LIVE Price Database Suppliers B2B suppliers Quality & badges Encyclopedia Articles
LONGEVITY TOPICS
NAD+ Precursors Sirtuin Activators Senolytics Autophagy Mitochondrial Hormesis
About PeptideCompare Business Network Contact Policy
Home / Encyclopedia / Khavinson Bioregulators / Ovagen
MONOGRAPH No. 055
EVIDENCE BASEPreclinical
TYPE
Natural peptide complex (cytomedin)
SEQUENCE
Proprietary complex
CAS
Not assigned
EU STATUS
Research only
WADA
Not listed
MIN PURITY
Lab-specific
Khavinson Bioregulators

Ovagen — EU research guide.

Ovagen is a Khavinson-series peptide bioregulator derived from liver tissue extract, proposed to support hepatocyte gene expression and liver cell regeneration. Ovagen is described as a natural tissue complex without one single defined sequence.

Last reviewed:

What is Ovagen?

Ovagen is a Khavinson-series peptide bioregulator derived from liver tissue extract, proposed to support hepatocyte gene expression and liver cell regeneration. Ovagen is described as a natural tissue complex without one single defined sequence.

What does the research show?

No peer-reviewed study under the name Ovagen was found; the closest published work is animal research on a related calf-liver polypeptide complex from the originating research group, without independent replication as of mid-2026.

EU legal status

Not approved as a medicine anywhere in the EU. Available only from a small number of specialist research vendors.

⚠ As a tissue-extract complex, identity and purity verification depend heavily on the supplier's COA — there is no simple molecular formula to check it against.
✓ Not yet tracked in PeptideCompare's price comparison. Verify any vendor's COA and sequence/identity claims directly before ordering — see our COA guide.
EVIDENCE SUMMARY
ANIMAL ONLY
Related liver polypeptide complex in animal hepatitis models — A 2020 review from the Khavinson group reports that a calf-liver polypeptide complex (named Ventvil, formerly Hepalin, in that paper, not explicitly Ovagen) and the tetrapeptide KEDA lowered bilirubin 2.5-3.5-fold and increased hepatocyte mitotic activity in rats, mice and rabbits with induced hepatitis or cirrhosis. The figures are given for both preparations together and come from the originating group.
NO HUMAN DATA
No primary study found under the name Ovagen — A PubMed search for the name Ovagen returned only unrelated veterinary reproduction papers on an FSH product with the same name; no peer-reviewed clinical or preclinical study of the liver bioregulator was found. Claims sold with the product rest on vendor and group-review material, not on verifiable trial data.

Molecular information

CAS number
Not assigned

Pharmacokinetics

No established human pharmacokinetic data. Published human PK parameters for this compound are not available; reported data are limited to animal models or absent. No curve is shown, to avoid implying data that does not exist.

Potency retained over time

Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.

Freezer −20 °C
36+ mo
Stable · >95% potency
Fridge 4 °C
3-4 mo
In use · after recon
Room 20 °C
10-13 days
Limited · moderate loss
Warm 37 °C+
2-3 days
Critical · rapid degradation

⚠ Modelled per compound from molecular structure — chain length, cyclisation, oxidation- and deamidation-prone residues and light sensitivity. Indicative only, not lab-measured per batch.

Ovagen is not yet in our price comparison

We expand EU supplier coverage every month.

References

  1. Review by the originating group on a calf-liver polypeptide complex and the tetrapeptide KEDA in animal hepatitis and cirrhosis models. It does not clearly name Ovagen, is a self-review, and contains no human liver trial. Kuznik BI, et al. The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology. Adv Gerontol. 2020;33(1):159-164. PubMed 32362099Source
  2. Review of short peptides and liver function from the same research environment. It mentions small human observations for the tetrapeptide KEDA (viral hepatitis A patients and healthy people) without group sizes in the parts read here, and no Ovagen-specific trial. It is not indexed with a PMID in the sources opened. Trofimova SV, et al. Role of short peptides in maintaining liver functional activity. EC Gastroenterology and Digestive System. 2021;8(11). Source

Related guides

Khavinson Bioregulators

Bolamin
Khavinson Bioregulators

Bronchogen
Khavinson Bioregulators

Cardiogen
PeptideCompare AssistantOnline · replies instantly
Hi! I help you quickly find the right page — about legality, COAs, badges or suppliers. No price advice, no dosing.
Try a question
Find a supplier Questions about a peptide? Read our articles Compare prices Is this legal in the EU? How to read a COA What do badges mean? Will customs stop my order? What is BAC water? Talk to a doctor first?
Navigation assistant · no medical advice